META 10-19 CAR T Therapy Delivers Durable Responses in High-Risk DLBCL
Early results from the phase 1 META 10-19 trial presented at the 2026 ASCO Annual Meeting showed encouraging outcomes for patients with high-risk relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Among 14 evaluable patients treated with ultra-low doses of the IL-10–expressing anti-CD19 CAR T-cell therapy, the objective response rate was 100%, and 92.9% achieved […]
META 10-19 CAR T Therapy Delivers Durable Responses in High-Risk DLBCL Read More ยป